Health
EU develops strategic reserves for chemical, biological and other emergencies
Includes 540.5 million Euros
(Source: European Commission)
This stockpile will consist of equipment and medicines, vaccines and other therapeutics to treat patients exposed to CBRN emergencies agents, as well as of rescEU decontamination reserve to provide decontamination equipment and expert response teams. As an immediate first step, the EU has mobilised its rescEU medical reserve to procure potassium iodide tablets which can be used to protect people from the harmful effects of radiation. Already almost 3 million iodide tablets have been delivered to Ukraine via the EU Civil Protection Mechanism, with the help of France and Spain.
On this occasion Janez Lenar?i?, Commissioner for Crisis Management said: “We are taking concrete measures to increase Europe's preparedness in the face of potential threats. We are setting up both a decontamination reserve and a new stockpile of equipment tailored to chemical, biological or nuclear emergencies. I am thankful for Member States in this effort. Our aim is to provide rapid response capabilities for our citizens if such an emergency ever occurs.”
Commissioner for Health and Food Safety, Stella Kyriakides, said: “Health security needs preparedness. Preparing for chemical, biological, radiological and nuclear threats is an essential element in keeping our citizens safe, and a key element of a strong European Health Union. HERA is our watchtower and has been working around the clock to support EU actions through the Civil Protection Mechanism to provide preparedness support to Ukraine and our Member States.”
People may be exposed to CBRN agents as a result of unintentional disasters (eg. a chemical plant leak, nuclear power plant incidents, the spread of an infectious disease) or intentional incidents (eg. a terrorist attack). Being prepared to address the risks of such threats is a key part of the EU CBRN stockpiling strategy.
The Commission is therefore developing under rescEU a strategic rescEU CBRN emergencies stockpile: The stockpile, which is designed withMember States, will include response equipment - such as personal protective equipment and detection, identification and monitoring devices - and medicines, vaccines and other therapeutics. The stockpile will make a crucial contribution to build CBRN resilience in the EU as it will include equipment and medicines that may be hard to manufacture in times of crisis or that may be suddenly required in larger amounts than what is available in national reserves. The CBRN stockpile is a first step towards establishing better capacities in response to nuclear power plant incidents, chemical facility emergencies, terrorist attacks or the spread of an infectious disease and many more.
Also rescEU decontamination reserve: This will comprise both staff and equipment to decontaminate people, infrastructure, buildings, vehicles or critical equipment that have been exposed to CBRN agents. Upon request of the affected Member State, the rescEU decontamination reserve can be deployed. The reserve will be developed and hosted by Croatia, Germany and Spain and will be 100% EU-financed with an initial budget of €66.7 million.
Extreme weather conditions and emerging threats, such as the coronavirus, but also CBRN incidents may overwhelm the ability of EU Member States to help each other, especially when several European countries face the same type of disaster simultaneously. Following the activation of the EU Civil Protection Mechanism, rescEU provides an extra layer of protection and ensures a faster and more comprehensive response to disasters. The rescEU reserve is 100% EU-financed and the EU Commission maintains, in close cooperation with the country hosting the reserve, control of their operation. In an emergency, the rescEU reserve provides assistance to all EU Member States, Participating States to the Mechanism and can also be deployed to EU neighbouring countries.
The Health Emergency preparedness and Response Authority (HERA) has been set up to strengthen Europe's ability to prevent, detect, and rapidly respond to cross-border health emergencies, be it natural or man made threat. HERA is doing so by funding the development, manufacturing and procurement of key medical countermeasures and equipment.
Liability for this article lies with the author, who also holds the copyright. Editorial content from USPA may be quoted on other websites as long as the quote comprises no more than 5% of the entire text, is marked as such and the source is named (via hyperlink).
